Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado-Joseph disease

Human Molecular Genetics

Volumn 24, Issue 19, 2015, Pages 5451-5463

  Duarte Neves, Joana ^a,b   Gonçalves, Nélio ^a   Cunha Santos, Janete ^a,b   Simões, Ana Teresa ^a   den Dunnen, Wilfred F A ^c   Hirai, Hirokazu ^d   Kügler, Sebastian ^e   Cavadas, Clãudia ^a,b   de Almeida, Luĩs Pereira ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 3; BRAIN DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 6; NEUROPEPTIDE Y; PARVOVIRUS VECTOR; ATXN3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN LEVEL; BRAIN REGION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MACHADO JOSEPH DISEASE; MOTOR COORDINATION; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADMINISTRATION AND DOSAGE; ANIMAL; C57BL MOUSE; CEREBELLUM; DEPENDOPARVOVIRUS; DISEASE MODEL; DOWN REGULATION; GENE THERAPY; GENE VECTOR; GENETICS; MACHADO-JOSEPH DISEASE; MALE; METABOLISM; PATHOPHYSIOLOGY; TRANSGENIC MOUSE; VISUAL CORTEX;

ANIMALS; ATAXIN-3; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBELLUM; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MACHADO-JOSEPH DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROPEPTIDE Y; VISUAL CORTEX;

EID: 84943793236     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv271     Document Type: Article

References (49)

1. Paulson, H.L. (2007) Dominantly inherited ataxias: lessons learned from Machado-Joseph disease/spinocerebellar ataxia type 3. Semin. Neurol., 27, 133-142.
2. Kawaguchi, Y., Okamoto, T., Taniwaki, M., Aizawa, M., Inoue, M., Katayama, S., Kawakami, H., Nakamura, S., Nishimura, M., Akiguchi, I. et al. (1994) CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat. Genet., 8, 221-228.
3. Paulson, H.L., Perez, M.K., Trottier, Y., Trojanowski, J.Q., Subramony, S.H., Das, S.S., Vig, P., Mandel, J.L., Fischbeck, K.H. and Pittman, R.N. (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron, 19, 333-344.
4. Durr, A., Stevanin, G., Cancel, G., Duyckaerts, C., Abbas, N., Didierjean, O., Chneiweiss, H., Benomar, A., Lyon-Caen, O., Julien, J. et al. (1996) Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann. Neurol., 39, 490-499.
5. Klockgether, T., Skalej, M.,Wedekind, D., Luft, A.R.,Welte, D., Schulz, J.B., Abele, M., Burk, K., Laccone, F., Brice, A. et al. (1998) Autosomal dominant cerebellar ataxia type I. MRIbased volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain, 121(Pt 9), 1687-1693.
6. Sudarsky, L. and Coutinho, P. (1995) Machado-Joseph disease. Clin. Neurosci., 3, 17-22.
7. D'Abreu, A., Franca, M.C. Jr, Paulson, H.L. and Lopes-Cendes, I. (2010) Caring forMachado-Joseph disease: current understanding and howto help patients. Parkinsonism. Relat. Disord., 16, 2-7.
8. Chen, X., Tang, T.S., Tu, H., Nelson, O., Pook, M., Hammer, R., Nukina, N. and Bezprozvanny, I. (2008) Deranged calciumsignaling and neurodegeneration in spinocerebellar ataxia type 3. J. Neurosci., 28, 12713-12724.
9. Koch, P., Breuer, P., Peitz, M., Jungverdorben, J., Kesavan, J., Poppe, D., Doerr, J., Ladewig, J., Mertens, J., Tuting, T. et al. (2011) Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature, 480, 543-546.
10. Simoes, A.T., Goncalves, N., Koeppen, A., Deglon, N., Kugler, S., Duarte, C.B. and Pereira de Almeida, L. (2012) Calpastatin- mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain, 135, 2428-2439.
11. Simoes, A.T., Goncalves, N., Nobre, R.J., Duarte, C.B. and Pereira de Almeida, L. (2014) Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease. Hum. Mol. Genet., 23, 4932-4944.
12. Chou, A.H., Yeh, T.H., Ouyang, P., Chen, Y.L., Chen, S.Y. and Wang, H.L. (2008) Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol. Dis., 31, 89-101.
13. Nascimento-Ferreira, I., Nobrega, C., Vasconcelos-Ferreira, A., Onofre, I., Albuquerque, D., Aveleira, C., Hirai, H., Deglon, N. and Pereira de Almeida, L. (2013) Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease. Brain, 136, 2173-2188.
14. Nascimento-Ferreira, I., Santos-Ferreira, T., Sousa-Ferreira, L., Auregan, G., Onofre, I., Alves, S., Dufour, N., Colomer Gould, V.F., Koeppen, A., Deglon, N. et al. (2011) Overexpression of the autophagic beclin-1 protein clearsmutant ataxin-3 and alleviates Machado-Joseph disease. Brain, 134, 1400-1415.
15. Evert, B.O., Vogt, I.R., Kindermann, C., Ozimek, L., de Vos, R.A., Brunt, E.R., Schmitt, I., Klockgether, T. and Wullner, U. (2001) Inflammatory genes are upregulated in expanded ataxin-3- expressing cell lines and spinocerebellar ataxia type 3 brains. J. Neurosci., 21, 5389-5396.
16. Goncalves, N., Simoes, A.T., Cunha, R.A. and de Almeida, L.P. (2013) Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease. Ann. Neurol., 73, 655-666.
17. Silva-Fernandes, A., Costa Mdo, C., Duarte-Silva, S., Oliveira, P., Botelho, C.M., Martins, L., Mariz, J.A., Ferreira, T., Ribeiro, F., Correia-Neves, M. et al. (2010) Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Neurobiol. Dis., 40, 163-176.
18. Silva, A.P., Xapelli, S., Grouzmann, E. and Cavadas, C. (2005) The putative neuroprotective role of neuropeptide Y in the central nervous system. Curr. Drug. Targets CNS Neurol. Disord., 4, 331-347.
19. Santos-Carvalho, A., Elvas, F., Alvaro, A.R., Ambrosio, A.F. and Cavadas, C. (2013) Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate. Cell Death Dis., 4, e636.
20. Croce, N., Gelfo, F., Ciotti, M.T., Federici, G., Caltagirone, C., Bernardini, S. and Angelucci, F. (2013) NPY modulates miR-30a-5p and BDNF in opposite direction in an in vitro model of Alzheimer disease: a possible role in neuroprotection? Mol. Cell Biochem., 376, 189-195.
21. Xapelli, S., Bernardino, L., Ferreira, R., Grade, S., Silva, A.P., Salgado, J.R., Cavadas, C., Grouzmann, E., Poulsen, F.R., Jakobsen, B. et al. (2008) Interaction between neuropeptide Y (NPY) and brain-derived neurotrophic factor in NPY-mediated neuroprotection against excitotoxicity: a role for microglia. Eur. J. Neurosci., 27, 2089-2102.
22. Aveleira, C.A., Botelho, M., Carmo-Silva, S., Pascoal, J.F., Ferreira-Marques, M., Nobrega, C., Cortes, L., Valero, J., Sousa-Ferreira, L., Alvaro, A.R. et al. (2015) Neuropeptide Y stimulates autophagy in hypothalamic neurons. Proc. Natl. Acad. Sci. USA, 112, E1642-E1651.
23. Ferreira, R., Santos, T., Cortes, L., Cochaud, S., Agasse, F., Silva, A.P., Xapelli, S. and Malva, J.O. (2012) Neuropeptide Y inhibits interleukin-1 beta-induced microglia motility. J. Neurochem., 120, 93-105.
24. Ferreira, R., Xapelli, S., Santos, T., Silva, A.P., Cristovao, A., Cortes, L. and Malva, J.O. (2010) Neuropeptide Y modulation of interleukin-1beta (IL-1b)-induced nitric oxide production in microglia. J Biol. Chem., 285, 41921-41934.
25. Alvaro, A.R., Martins, J., Costa, A.C., Fernandes, E., Carvalho, F., Ambrosio, A.F. and Cavadas, C. (2008) Neuropeptide Y protects retinal neural cells against cell death induced by ecstasy. Neuroscience, 152, 97-105.
26. Decressac, M., Pain, S., Chabeauti, P.Y., Frangeul, L., Thiriet, N., Herzog, H., Vergote, J., Chalon, S., Jaber, M. and Gaillard, A. (2012) Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiol. Aging, 33, 2125-2137.
27. Decressac, M.,Wright, B., Tyers, P., Gaillard, A. and Barker, R. A. (2010) Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp. Neurol., 226, 24-32.
28. Alves, S., Nascimento-Ferreira, I., Dufour, N., Hassig, R., Auregan, G., Nobrega, C., Brouillet, E., Hantraye, P., Pedroso de Lima, M.C., Deglon, N. et al. (2010) Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Hum. Mol. Genet., 19, 2380-2394.
29. Alves, S., Regulier, E., Nascimento-Ferreira, I., Hassig, R., Dufour, N., Koeppen, A., Carvalho, A.L., Simoes, S., de Lima, M.C., Brouillet, E. et al. (2008) Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Hum. Mol. Genet., 17, 2071-2083.
30. Greengard, P., Allen, P.B. and Nairn, A.C. (1999) Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron, 23, 435-447.
31. de Almeida, L.P., Ross, C.A., Zala, D., Aebischer, P. and Deglon, N. (2002) Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci., 22, 3473-3483.
32. Ferrer, I., Goutan, E., Marin, C., Rey, M.J. and Ribalta, T. (2000) Brain-derived neurotrophic factor in Huntington disease. Brain. Res., 866, 257-261.
33. Hock, C., Heese, K., Hulette, C., Rosenberg, C. and Otten, U. (2000) Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol., 57, 846-851.
34. Xie, Y., Hayden, M.R. and Xu, B. (2010) BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J. Neurosci., 30, 14708-14718.
35. Chan-Palay, V., Lang, W., Haesler, U., Kohler, C. and Yasargil, G. (1986) Distribution of altered hippocampal neurons and axons immunoreactive with antisera against neuropeptide Y in Alzheimer's-type dementia. J. Comp. Neurol., 248, 376-394.
36. Davies, C.A., Morroll, D.R., Prinja, D., Mann, D.M. and Gibbs, A. (1990) A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease. J. Neurol. Sci., 96, 59-73.
37. Ramos, B., Baglietto-Vargas, D., del Rio, J.C., Moreno-Gonzalez, I., Santa-Maria, C., Jimenez, S., Caballero, C., Lopez-Tellez, J.F., Khan, Z.U., Ruano, D. et al. (2006) Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol. Aging, 27, 1658-1672.
38. Mellios, N., Huang, H.S., Grigorenko, A., Rogaev, E. and Akbarian, S. (2008) A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. Hum. Mol. Genet., 17, 3030-3042.
39. Sheriff, S., Chance, W.T., Fischer, J.E. and Balasubramaniam, A. (1997) Neuropeptide Y treatment and food deprivation increase cyclic AMP response element-binding in rat hypothalamus. Mol. Pharmacol., 51, 597-604.
40. Tao, X., Finkbeiner, S., Arnold, D.B., Shaywitz, A.J. and Greenberg, M.E. (1998) Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron, 20, 709-726.
41. Bovolenta, R., Zucchini, S., Paradiso, B., Rodi, D., Merigo, F., Navarro Mora,G., Osculati, F., Berto, E.,Marconi, P.,Marzola, A. et al. (2010) Hippocampal FGF-2 and BDNFoverexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures. J Neuroinflammation, 7, 81.
42. Wu, S.Y.,Wang, T.F., Yu, L., Jen, C.J., Chuang, J.I., Wu, F.S., Wu, C.W. and Kuo, Y.M. (2011) Running exercise protects the substantia nigra dopaminergic neurons against inflammationinduced degeneration via the activation of BDNF signaling pathway. Brain Behav. Immun., 25, 135-146.
43. Maccioni, R.B., Rojo, L.E., Fernandez, J.A. and Kuljis, R.O. (2009) The role of neuroimmunomodulation in Alzheimer's disease. Ann. N. Y. Acad. Sci., 1153, 240-246.
44. Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A.L., Citron, M. and Landreth, G. (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci., 23, 7504-7509.
45. Ferreira, R., Santos, T., Viegas, M., Cortes, L., Bernardino, L., Vieira, O.V. and Malva, J.O. (2011) Neuropeptide Y inhibits interleukin-1beta-induced phagocytosis by microglial cells. J Neuroinflammation, 8, 169.
46. Torashima, T., Koyama, C., Iizuka, A., Mitsumura, K., Takayama, K., Yanagi, S., Oue, M., Yamaguchi, H. and Hirai, H. (2008) Lentivector-mediated rescue from cerebellar ataxia in a mouse model of spinocerebellar ataxia. EMBO Rep., 9, 393-399.
47. de Almeida, L.P., Zala, D., Aebischer, P. and Deglon, N. (2001) Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol. Dis., 8, 433-446.
48. Sousa-Ferreira, L.,Garrido,M.,Nascimento-Ferreira, I.,Nobrega, C., Santos-Carvalho, A., Alvaro, A.R., Rosmaninho-Salgado, J., Kaster, M., Kugler, S., de Almeida, L.P. et al. (2011) Moderate long-term modulation of neuropeptide Y in hypothalamic arcuate nucleus induces energy balance alterations in adult rats. PLoS One, 6, e22333.
49. Paxinos, G., Franklin, K.B.J. and Franklin, K.B.J. (2001) TheMouse Brain in Stereotaxic Coordinates. Academic Press, San Diego.